Daily non-political popular news in brief.

Phase III trials of cellulose sulfate microbicide for HIV prevention closed

CONRAD, a reproductive health research organization, announced today that it has halted a Phase III clinical trial of cellulose sulfate -- a topical microbicide gel being tested for HIV prevention in women -- because preliminary results indicated that cellulose sulfate could lead to an increased risk of HIV infection in women who use the compound. The trial was being conducted in South Africa, Benin, Uganda, and India.

Read more »

Keywords: phase, iii, trials, cellulose, sulfate, microbicide, hiv, prevention, closed, trial

« Previous | Next »

Similar news on "Phase III trials of cellulose sulfate microbicide for HIV prevention closed":

1. Leading advocates express support for microbicide research, despite disappointing trial results
   01-31-2007 · EurekAlert!
   HIV prevention advocates from three major civil society organizations today emphasized the importance of continued research into new HIV prevention options, despite the recent discontinuation of the phase III effectiveness trials of the microbicide candidate, cellulose sulfate (CS).
   Similar news · Read more »
   
2. Safety of new microbicide for HIV prevention to be tested in young women in US trial
   07-09-2007 · EurekAlert!
   In an effort to help stem the tide of the HIV/AIDS epidemic, particularly in women, researchers have launched a clinical safety trial of a topical vaginal microbicide with a unique molecular structure that holds promise for preventing the sexual transmission of HIV. The Microbicide Trials Network is leading the NIH-funded study in which VivaGel is being tested for the first time in sexually active young women to determine its safety, acceptability and ease of use.
   Similar news · Read more »
   
3. Human trial results show excellent safety data, from Geovax's DNA/MVA AIDS vaccines
   02-06-2007 · EurekAlert!
   GeoVax Labs, Inc. an Atlanta-based biotechnology company, today reported successful early results from two ongoing AIDS prevention Phase I human vaccine trials. Results from the first low-dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine. Results from a second larger full-dose trial also indicate a good safety profile in participants.
   Similar news · Read more »
   
4. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
   11-15-2007 · EurekAlert!
   Advanced Life Sciences Holdings, Inc. today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia, the sixth leading cause of death in the United States.
   Similar news · Read more »
   
5. Phase I study of novel gene therapy for HIV
   11-06-2006 · EurekAlert!
   The results are in for Phase I clinical trials of a gene therapy for AIDS. The trial was conducted at U-Penn where five patients with chronic HIV who had failed prior therapies were given a one-time infusion. They all tolerated the therapy and showed improved immune system response. This is the first publication of an effective gene therapy for AIDS to show positive clinical results in the peer review literature.
   Similar news · Read more »
   
6. First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
   02-14-2007 · EurekAlert!
   The first "antisense" drug to be tested in chronic lymphocytic leukemia (CLL) shows benefit in a phase III clinical trial for a specific subset of patients - those who are still sensitive to a chemotherapy drug often used to treat this cancer.
   Similar news · Read more »
   
7. Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids
   12-09-2007 · EurekAlert!
   Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, MD, at the American Society of Hematology's annual meeting.
   Similar news · Read more »
   
8. Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
   01-31-2008 · EurekAlert!
   Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
   Similar news · Read more »
   
9. International AIDS Vaccine Initiative (IAVI) statement on male circumcision
   12-14-2006 · EurekAlert!
   The International AIDS Vaccine Initiative (IAVI) issued this statement today following a National Institutes of Health (NIH) decision to end two clinical trials of adult male circumcision in Uganda and Kenya. The NIH's Data Safety and Monitoring Board (DSMB), reviewing interim data, found that medically performed circumcision significantly protected men in the trial from HIV infection.
   Similar news · Read more »
   
10. Anti-herpes treatment reduces HIV levels in women infected with both viruses
    02-21-2007 · EurekAlert!
    Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are publishedTreating women who are infected with both the HSV-2 and HIV viruses with anti-herpes treatment can reduce the amount of HIV in the blood and genital secretions, according to the results of a trial published today in the New England Journal of Medicine.
    Similar news · Read more »